The transaction would give Philip Morris roughly 58 per cent ownership of the new company, with Altria holding the rest, according to a person familiar with the terms who asked not to be identified because the details haven’t been made public.
They are considering a no-premium deal based on the companies’ closing share prices on August 23, according to the person. The companies would aim to close the deal within six months and expect to make no divestitures, the person said.
There’s been speculation that the companies might get back together. On Monday, Wells Fargo published a research note that said a deal could make sense now, in part because Altria has a stake in the vaping company Juul.
A reunification would combine two of the most popular smoking alternative products: IQOS and Juul. Philip Morris has been plowing billions of dollars in promoting IQOS, a heat-not-burn product used by millions consumers outside the US. Altria meanwhile has invested $US12.8 billion in e-cigarette upstart Juul, which has catapulted itself to the US industry leader in smoking alternatives in just a few years.
Altria also has been planning to start selling IQOS in the US this year, testing out demand in the Atlanta area with a store opening next month.
Philip Morris said in a statement that no agreement has been formally reached and any deal would be subject to board, shareholder and regulatory approval. Altria also issued a statement confirming the talks.
Like Hollywood, which has been churning out films based on blockbusters of decades past, Wall Street bankers seem to be running out of new ideas. Earlier this month, CBS agreed to reunite with Viacom in an $US11.7 billion transaction, 13 years after the two media giants split.
Analysts were largely positive on a potential tie-up between Altria and Philip Morris after speculation Monday afternoon that something was brewing. RBC Capital Markets analyst Nik Modi saw several strategic reasons for a deal, including geographic alignment with international competitors and full economic benefit of IQOS in the US and global access for Juul.
“The potential to reunite the companies has been often discussed, but we did not believe this would occur given the heavy regulatory burden in the US market and its weakening growth profile,” Stifel analyst Chris Growe said in a note. “Perhaps the FDA’s approval of IQOS changed that thinking.”
The tie-up would face little antitrust risk because the companies’ brands don’t compete in the same markets, said Kenneth Shea, an analyst at Bloomberg Intelligence. That contrasts with the last major tobacco deal: Reynolds American’s 2015 takeover of Lorillard. The Federal Trade Commission, which reviews tobacco deals, required Reynolds to sell four brands to Imperial Tobacco Group to resolves antitrust concerns.
One area of likely scrutiny would be the combined company’s control of the vaping market, said Shea, given Altria’s 35 per cent stake in Juul and its agreement to sell IQOS in the US for Philip Morris.
“Depending on how regulators define the vapour market, there could be potential for perceived excessive control,” he said.